Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 5/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HTR1E | P28566 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539769 | 0.88 | CHRNB2 (0.57) | HTR2ATRPM8GPR84HTR1ASLC6A4 | |
| SCHEMBL28370930 | 0.82 | HTR2A (0.61) | HTR2ATRPM8GPR84HTR1ASLC6A4 | |
| SCHEMBL28374497 | 0.82 | MPO (0.61) | HTR2ATRPM8GPR84HTR1ASLC6A4 | |
| SCHEMBL8404321 | 0.82 | HTR2A (0.61) | HTR2AHTR1ASLC6A4MTNR1AMTNR1B | |
| SCHEMBL5430044 | 0.82 | HTR2A (0.80) | HTR2ATRPM8GPR84HTR1ASLC6A4 | |
| SCHEMBL2539333 | 0.79 | SLC6A4 (0.57) | HTR1ASLC6A4DRD2DRD3 | |
| SCHEMBL29440786 | 0.79 | HTR2A (0.64) | HTR2ATRPM8GPR84HTR1ASLC6A4 | |
| SCHEMBL28704885 | 0.79 | HTR2A (0.64) | HTR2ATRPM8GPR84HTR1ASLC6A4 | |
| SCHEMBL2187283 | 0.78 | PKM (0.62) | HTR2ATRPM8GPR84HTR1AHTR2C | |
| SCHEMBL30995725 | 0.78 | PKM (0.62) | HTR2ATRPM8GPR84HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-1737461-B1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| EP-2431369-A2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC Therapeutics, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1871375-B1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PTC THERAPEUTICS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-8076352-B2 | Administration of carboline derivatives useful in the treatment of cancer and other diseases | PTC THERAPEUTICS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-7601840-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | VEGFA, FLT4, FLT1 | HTR2A 1527/4885TRPM8 4861/4885GPR84 1127/4885 |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | HTR2A 1527/4885TRPM8 4861/4885GPR84 1127/4885 |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | HTR2A 1837/4885TRPM8 4849/4885GPR84 1097/4885 |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | VEGFA, FLT4, KDR | HTR2A 2036/4885TRPM8 4258/4885GPR84 721/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | HTR2A 824/4885TRPM8 3424/4885GPR84 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.